Rozanolixizumab clinical efficacy. (A) Mean platelet count over time after rozanolixizumab subcutaneous infusion (per protocol set). Arrows indicate time of rozanolixizumab subcutaneous infusion. *Baseline platelet counts were derived from central laboratory data. (B) Time to first clinically relevant response (platelet count ≥50 × 10⁹/L) in the patients classified as responders (per protocol set).